Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $50.00 price target on the stock.
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $54.00 price target on the stock.
Correction: Amarna Therapeutics announces formation of Scientific Advisory Board to support advancement of groundbreaking Nimvec™ AM510 gene therapy against Type 1 Diabetes [Yahoo! Finance]
Amarna Therapeutics announces formation of Scientific Advisory Board to support advancement of groundbreaking Nimvec™ AM510 gene therapy against Type 1 Diabetes [Yahoo! Finance]
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $50.00 price target on the stock.